Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Executive Summary
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
You may also be interested in...
Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather
Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.
Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Hong Kong Ushers in 'New Era' For Bioventures As Listing Rules Eased
The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.
Need a specific report? 1000+ reports available
Buy Reports